---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-036343"
form_type: "8-K/A"
ticker: "BLFS"
cik: "0000834365"
company_name: "BIOLIFE SOLUTIONS INC"
filed_at: "2024-08-09T23:59:59+00:00"
generated_at: "2026-05-31T10:37:24.023474+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioLife Solutions corrects Q2 earnings; raises full-year revenue guidance to $99-101M

## Summary
- Q2 total revenue $28.3M, down 3% YoY but up 6% sequentially; Cell Processing up 11% sequentially.
- GAAP net loss from continuing ops $7.1M (incl $4.1M write-off) versus $5.5M loss a year ago.
- Non-GAAP adjusted EBITDA $4.8M or 17% of revenue, up from $1.7M or 6% in Q2 2023.
- FY 2024 total revenue guidance raised to $99-101M; Cell Processing guidance raised to $70-71M.
- 8-K/A corrects prior release to reduce stock compensation by $2.1M from discontinued operations.

## SEC filing metadata
- accession: 0001628280-24-036343
- form_type: 8-K/A
- ticker: BLFS
- cik: 0000834365
- company_name: BIOLIFE SOLUTIONS INC
- filed_at: 2024-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/834365/000162828024036343/0001628280-24-036343-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/834365/000162828024036343/blfs-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-036343
- JSON: https://secwatch.observer/filing/0001628280-24-036343.json
- Plain text: https://secwatch.observer/filing/0001628280-24-036343.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.